Table 1.

Patient Demographics at the Time of Index Bleed for the Octreotide-Treated Group

VariablesRebleed at 6 mo (n=12)No Rebleed at 6 mo (n=39)P Value
Age, y65±1164±100.9
Sex (male)58%72%0.5
Race0.2
 White50%67%
 Black42%31%
 Other8%3%
Median time from LVAD implant (IQR)262 (45–1275)166 (69–551)0.4
INTERMACS profile0.2
 Profile 19%24%
 Profile 255%40%
 Profile 39%24%
 Profile 4 or 527%13%
Destination therapy50%51%1.0
Medical history
 Gastrointestinal bleed before LVAD33%5%0.02
 Diabetes mellitus58%48%0.7
 Atrial fibrillation8%44%0.04
 Hypertension75%62%0.5
 CKD stage III or greater33%44%0.7
 Peripheral vascular disease8%10%1.0
 COPD25%18%0.7
 Ischemic heart disease75%62%0.5
Prior LVAD-related complications
 Superficial driveline infection0%16%0.3
 Pump infection0%5%1.0
 Bacteremia33%28%0.7
 Pump thrombosis17%13%0.7
 Ischemic CVA0%13%0.3
 Hemorrhagic CVA0%3%1.0
 Peripheral arterial embolic event8%5%0.6
  • CKD indicates chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; IQR, interquartile range; and LVAD, left ventricular assist device.